Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).

被引：0

作者：

Gambacorti-Passerini, Carlo

Abboud, Camille N.

Gjertsen, Bjorn T.

Brummendorf, Tim H.

Smith, B. Douglas

Giraldo-Castellano, Pilar

Olsson-Stromberg, Ulla

Saussele, Susanne

Bardy-Bouxin, Nathalie

Viqueira, Andrea

Leip, Eric

Leone, Jocelyn M.

Rosti, Gianantonio

Watts, Justin M.

Giles, Frank

Hochhaus, Andreas

机构：

[1] Univ Milano Bicocca, Monza, Italy

[2] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA

[3] Helse Bergen, Haukeland Univ Hosp, Bergen, Norway

[4] Univ Bergen, Bergen, Norway

[5] Univ Klinikum RWTH Aachen, Aachen, Germany

[6] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] ISCIII, CIBERER, Hosp Miguel Servet, Zaragoza, Spain

[8] Uppsala Univ, Uppsala, Sweden

[9] Univ Hosp, Dept Hematol, Uppsala, Sweden

[10] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany

[11] Pfizer Int Operat Oncol, Paris, France

[12] Pfizer SLU, Madrid, Spain

[13] Pfizer Inc, Cambridge, MA USA

[14] Pfizer Inc, Cambridge, MA USA

[15] Univ Bologna, Univ Hosp, Rome, Italy

[16] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[17] Dev Therapeut Consortium, Chicago, IL USA

[18] Univ Klinikum Jena, Jena, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7012

引用

页数：2